

Pursuant to the provisions of article 227 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("**Grifols**") hereby informs about the following

OTHER RELEVANT INFORMATION

Grifols informs that it has closed the transaction to acquire 25 U.S. based plasma donation centers from BPL Plasma, Inc, a subsidiary of Bio Products Laboratory Holdings Limited, for a total purchase price of USD 370 million. The 25 centers acquired are authorized by the U.S. Food and Drug Administration (FDA) and the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) and during last year collected approximately one million liters of plasma. Grifols will have immediate access to the plasma obtained from these centers.

The transaction has received the applicable regulatory clearances, and will be financed from Grifols' own resources.

In 2021, Grifols is ready for a rebound in its plasma-collection levels in the wake of wider vaccination deployments and the ease of COVID-19 constraints. Grifols is also advancing on the execution of its expansion plan, comprising organic and inorganic growth. As part of its organic efforts, the company plans to open between 15 and 20 new plasma centers in 2021.

This acquisition is aligned with Grifols' global expansion and plasma-supply diversification strategy, with 344 plasma centers worldwide: 289 in the U.S. following this transaction and 55 in Europe across Germany, Austria and, recently Hungary. Likewise, Grifols remains committed to increasing its supply of plasma and plasma-derived therapies to ensure patients continue to receive the treatments and healthcare they need.

In Barcelona, on 1 March 2021

Nuria Martín Barnés
Secretary to the Board of Directors